Equities research analysts forecast that Replimune Group, Inc. (NASDAQ:REPL – Get Rating) will announce ($0.60) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Replimune Group’s earnings, with the highest EPS estimate coming in at ($0.57) and the lowest estimate coming in at ($0.65). Replimune Group posted earnings of ($0.41) per share in the same quarter last year, which would indicate a negative year over year growth rate of 46.3%. The firm is scheduled to issue its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Replimune Group will report full-year earnings of ($2.26) per share for the current financial year, with EPS estimates ranging from ($2.30) to ($2.23). For the next year, analysts anticipate that the company will post earnings of ($2.70) per share, with EPS estimates ranging from ($2.93) to ($2.31). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that that provide coverage for Replimune Group.
Replimune Group (NASDAQ:REPL – Get Rating) last released its quarterly earnings data on Thursday, February 3rd. The company reported ($0.57) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.01.
In other news, major shareholder Fund Iv L.P. Omega sold 16,500 shares of the firm’s stock in a transaction that occurred on Monday, March 14th. The stock was sold at an average price of $15.42, for a total value of $254,430.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 40.30% of the stock is owned by company insiders.
Several large investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company lifted its stake in shares of Replimune Group by 3.0% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 15,945 shares of the company’s stock valued at $473,000 after purchasing an additional 470 shares during the last quarter. California State Teachers Retirement System lifted its stake in shares of Replimune Group by 1.8% in the 4th quarter. California State Teachers Retirement System now owns 33,843 shares of the company’s stock valued at $917,000 after purchasing an additional 586 shares during the last quarter. Voya Investment Management LLC lifted its stake in shares of Replimune Group by 5.6% in the 3rd quarter. Voya Investment Management LLC now owns 11,071 shares of the company’s stock valued at $328,000 after purchasing an additional 587 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Replimune Group by 2.1% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 31,729 shares of the company’s stock worth $539,000 after buying an additional 646 shares during the period. Finally, Royal Bank of Canada raised its holdings in shares of Replimune Group by 15.8% in the third quarter. Royal Bank of Canada now owns 4,804 shares of the company’s stock worth $143,000 after buying an additional 657 shares during the period. 75.42% of the stock is owned by institutional investors and hedge funds.
NASDAQ REPL opened at $16.89 on Monday. The firm has a market cap of $797.38 million, a price-to-earnings ratio of -8.16 and a beta of 2.29. The company has a quick ratio of 23.39, a current ratio of 23.39 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average price of $17.07 and a 200-day moving average price of $22.84. Replimune Group has a twelve month low of $14.98 and a twelve month high of $40.22.
Replimune Group Company Profile (Get Rating)
Replimune Group, Inc, a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma.
- Get a free copy of the StockNews.com research report on Replimune Group (REPL)
- World Wresting Entertainment Stock is Hulking Up
- High-Yield Weyco Group Returns To Reasonable Levels
- MarketBeat Podcast: Alternative Investing Strategies Despite Market Volatility
- Limelight Networks Stock is a Speculative Turnaround Opportunity
- The Selloff In SiteOne Landscape Supply Is Overextended
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.